profit from every $100 of sales.
$0$100
Ginkgo Bioworks Holdings
$10.23-0.20% today
+22.4% in 1 year
1-year low $5.481-year high $14.98
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Ginkgo Bioworks Holdings sold, what it kept, and what it did with the cash.
Sales went from $478 million in 2022 to $170 million in 2025, with -$313 million of profit last year.
SalesProfit
Ginkgo Bioworks Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Ginkgo Bioworks Holdings | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Ginkgo Bioworks Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 478 | 251 | 227 | 170 | |
| 273 | 197 | 182 | 123 | |
| -2,209 | -768 | -488 | -304 | |
| -2,079 | -822 | -484 | -255 | |
| -2,105 | -893 | -547 | -313 | |
| -50.00 | -18.37 | -10.54 | -5.64 | |
| 57.3% | 78.5% | 80.4% | 72.4% | |
| -462.4% | -305.5% | -214.8% | -178.6% | |
| -440.6% | -355.1% | -240.9% | -183.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 2,539 | 1,665 | 1,377 | 1,120 |
| Cash | 1,316 | 944 | 562 | 167 |
| Total debt | 443 | 239 | 468 | 440 |
| Total liabilities | 803 | 568 | 661 | 611 |
| 1,736 | 1,097 | 716 | 509 | |
| 42 | 49 | 52 | 55 | |
| -76.9% | -52.8% | -36.5% | -26.1% | |
| -121.2% | -81.4% | -76.4% | -61.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -252 | -296 | -320 | -171 | |
| 52 | 41 | 63 | 8 | |
| -304 | -336 | -382 | -179 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | – | – | |
| 1,931 | 230 | 112 | 82 |
Valuation
- –
- –
- –
- 1.0×
- 3.9×
- –
- –
- -27.0%
- -47.2%
- 0.0%
Profitability
- 72.4%
- -178.6%
- -183.8%
- -145.9%
- -31.1%
- -72.6%
- -57.3%
- -29.5%
- -31.2%
- 157.6%
Growth
- −29.1%
- –
- +53.2%
- –
- +13.9%
Financial health
- –
- 0.93
- 39.8%
- –
- 5.15
- 5.15
- 0.14
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 15%of 952
Bottom 1%of 883
Bottom 3%of 870
Bottom 2%of 985
What analysts expect
- Average price target
- $7.84
- Range
- $4.35 – $12.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -1.28 | -1.21 | −5.7% |
| Feb 26, 2026 | -1.42 | -1.80 | +21.1% |
| Nov 6, 2025 | -1.45 | -1.24 | −16.9% |
| Aug 7, 2025 | -1.10 | -1.44 | +23.6% |
| May 6, 2025 | -1.58 | -1.23 | −28.5% |
| Feb 25, 2025 | -1.82 | -1.45 | −25.5% |
| Nov 12, 2024 | -1.08 | -2.40 | +55.0% |
| Aug 8, 2024 | -3.20 | -3.20 | +0.0% |
News
Guardant Health loses challenge regarding DNA sequencing patentSeeking Alpha · Oct 15, 2026Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key FactsYahoo Finance · Sep 16, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
60Pass
Philip Fisher
34No pass
Peter Lynch
20No pass
Joel Greenblatt
0No pass
Charlie Munger
23No pass
Terry Smith
27No pass
Questions about Ginkgo Bioworks Holdings
Is Ginkgo Bioworks Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Ginkgo Bioworks Holdings AI analysis
What does Ginkgo Bioworks Holdings do?
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It is in Biotechnology.
Does Ginkgo Bioworks Holdings pay a dividend?
No. Ginkgo Bioworks Holdings does not pay a dividend at the moment.
Is Ginkgo Bioworks Holdings stock halal?
No. Ginkgo Bioworks Holdings does not pass our halal screen: its debt is 66% of its market value, at or above the 33% limit. How we check
How has Ginkgo Bioworks Holdings stock done over the past year?
Up 22.4% over the past twelve months, to $10.23. It traded between $5.48 and $14.98 and is 31.7% below its high.
Who are Ginkgo Bioworks Holdings's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Ginkgo Bioworks Holdings's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.